{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-016001","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.093284+00:00","generated_at":"2026-05-17T05:26:00.727740+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anebulo posts Q4 net loss $2.1M; starts Phase 1 IV selonabant; proposes reverse split for going private","bullets":["Q4 FY2025 net loss of $2.1M ($0.05/shr) vs $1.3M ($0.05/shr) prior year; full-year net loss $8.5M ($0.25/shr) vs $8.2M ($0.32/shr).","First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric acute cannabis toxicity on September 25, 2025.","Received year-2 NIDA/NIH grant of $994,300 to support the SAD study of IV selonabant.","Board approved reverse stock split to reduce record holders below 300 as part of proposed going-private transaction; special meeting pending.","Cash and cash equivalents $11.6M at June 30, 2025; additional $3M available under loan agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-016001","json":"https://secwatch.observer/filing/0001493152-25-016001.json","markdown":"https://secwatch.observer/filing/0001493152-25-016001.md","text":"https://secwatch.observer/filing/0001493152-25-016001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315225016001/0001493152-25-016001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315225016001/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:26:00.727740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}